Latest News for: Placebo

Edit

Placebo announce huge 30th anniversary tour with Manchester show set for this year

Manchester Evening News 18 Mar 2026
It's all part of a big 'celebration of where we began' ... .
Edit

Placebo announced 5 new events

Ents24 18 Mar 2026
Sat 28th Nov. Motorpoint Arena Nottingham Mon 30th Nov. The OVO Hydro, Glasgow Fri 4th Dec. Co-op Live Arena, Manchester Sat 5th Dec. OVO Arena, Wembley, London Mon 7th Dec. Utilita Arena Cardiff ... .
Edit

Placebo Glasgow Hydro Ticket Presales and Prices: How to see Brian Molko and his alt ...

The Scotsman 18 Mar 2026
It’s a homecoming of sorts for lead singer Brian Molko, who spent part of his childhood living in Scotland ....
Edit

Placebo announce RE:CREATED 30th anniversary UK and European tour and reimagined version of debut album

The Daily Mail 18 Mar 2026
Placebo are revisiting the album that launched their career, announcing Placebo RE.CREATED - a newly reworked version of their 1996 debut - which arrives on June 19 ....
Edit

Placebo announce ‘RE:CREATED’ 30th anniversary UK and European tour and reimagined version of debut album

NME 18 Mar 2026
Placebo have announced ‘RE.CREATED’ – a new reworking of their 1996 debut album – as well as a new UK and European tour that will see them perform tracks from their first two albums ... Placebo interview ... Placebo ‘RE.CREATED’ 2026 artwork.
Edit

Placebo mark 30 years of debut album with new RE:CREATED Album and arena tour

Music News 18 Mar 2026
Placebo are revisiting the album that launched their career, announcing Placebo RE.CREATED — a newly reworked version of their 1996 debut — which arrives on June 19 ... Placebo RE.CREATED tracklisting..
Edit

Efficacy and safety of Descartes-08 in AChR+ generalized myasthenia gravis: subgroup analysis of a Phase 2b randomized, placebo-controlled trial (Cartesian Therapeutics Inc)

Public Technologies 12 Mar 2026
). Efficacy and safety of Descartes-08 in AChR+ generalized myasthenia gravis. subgroup analysis of a Phase 2b randomized, placebo-controlled trial. Tuan Vu, Hacer Durmuş, Hafsa Kamboh, Renee Fedak, C. Andrew Stewart, Miloš D ... Howard, Jr ... 106,000+ ... 1 ... 1 ... doi.
Edit

The Market’s Favorite Placebo: Strategic Oil Reserves (Siebert Financial Corporation)

Public Technologies 11 Mar 2026
) Energy-driven inflation is back in focus as the Strait of Hormuz disruption collides with Fed policy expectations ... [...]. This is an abstract of the document.
Edit

Garbage’s Shirley Manson on playing for Robert Smith with Placebo, beach balls, and the future ...

NME 11 Mar 2026
The night will also see Garbage share the stage with fellow ’90s rock outsiders Placebo, who’ll be opening with a stripped-back set as they gear up to celebrate 30 years since their debut album.
Edit

Study: Anitdepressants versus placebo for generalised anxiety disorder

Montana Standard 01 Mar 2026
Read the study summary here ... .
Edit

Response Drivers in Sebetralstat Placebo-controlled Clinical Trials (Kalvista Pharmaceuticals Inc)

Public Technologies 27 Feb 2026
010 Response Drivers in Sebetralstat Placebo-controlled Clinical Trials ... Placebo Sebetralstat 600 mg ... Placebo Sebetralstat 600 mg ... achieved relief sooner than placebo ... achieved relief sooner than placebo ... achieved relief sooner than placebo ... Placebo.
Edit

Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo ...

The Galveston Daily News 20 Feb 2026
BOSTON--(BUSINESS WIRE)--Feb 20, 2026-- ....
Edit

Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials

Pharmiweb 20 Feb 2026
Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials ... with placebo response.
Edit

Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Nasdaq Globe Newswire 17 Feb 2026
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025 ... .
Edit

Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder (Form 6-K) (Cybin Inc)

Public Technologies 17 Feb 2026
) Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder ... -7.35) versus placebo at two weeks ... 12% for placebo, with remission rates (MADRS ≤10) at 29% vs.

Article Search

tools
×
×
×
×